Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Biomarker Correlates and Clinical Activity of Cevostamab in Patients (pts) with Triple-Class Refractory Multiple Myeloma (MM) Who Have Received ≥1 Prior B-Cell Maturation Antigen (BCMA)-Targeted Bispecific Antibody (BsAb): Results from the Phase I/II CAMMA 2 Study

Michel Delforge, Joshua Richter, Yael C. Cohen, Paolo Corradini, Douglas W Sborov, Alexander M. Lesokhin, Jesus G Berdeja, Moshe E Gatt, Laura Paris, Laura Rosinol Dachs, Hang Quach, Manisha Kanwar, Olivier Catalani, Paresh Sewpaul, Elisabeth Wassner-Fritsch, Ameet Mishra, Kerstin Trunzer, Shaji Kumar

Blood (2024) 144 (Supplement 1): 4732.

https://doi.org/10.1182/blood-2024-199519

Published: 2024

Journal Articles

Dynamics of Activated CD8+ T-cells and Decreased Osteoclasts in the Tumor Microenvironment are Associated with Clinical Efficacy of Anti-PD-L1 and Anti-CD38 Combination Treatment in Relapsed or Refractory Multiple Myeloma

Aparna Raval, PhD, Hearn Jay Cho, MD PhD, Cherie Green, BS, Elisabeth Wassner Fritsch, PharmD, Connie Ma, MS, Naomi Chang, MSc, Mark Yan, PhD, Mark Kockx, MD PhD, Shine Shen, MS, Ling-Yuh Huw, PhD, Emily Balestiere, BA, Marina Lipkind, BS, Huang Huang, MSc, Michelle Byrtek, PhD, Dawn Colburn, PharmD, BCOP, Sandy W. Wong, Jeffrey M. Venstrom, MD PhD, Joanne I Adamkewicz, PhD

Blood (2019) 134 (Supplement_1): 1907.

https://doi.org/10.1182/blood-2019-123652

Published: 2019

Journal Articles

Atezolizumab in Combination with Daratumumab with or without Lenalidomide or Pomalidomide: A Phase Ib Study in Patients with Multiple Myeloma

Hearn Jay Cho, MD, Luciano J Costa, MD PhD, Faith E. Davies, MD, Natalia Neparidze, MD, Ravi Vij, Yuning Feng, Anastasia Teterina, Elisabeth Wassner Fritsch, Michael Wenger, Jonathan L Kaufman, MD

Blood (2018) 132 (Supplement 1): 597.

https://doi.org/10.1182/blood-2018-99-114960

Published: 2018

Journal Articles

Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN Study

Bruce D. Cheson, Marek Trněný, Kamal Bouabdallah, MD, Gregory Dueck, John Gribben, Pieternella J Lugtenburg, MD PhD, Oliver Press, Gilles A. Salles, Günter Fingerle-Rowson, Federico Mattiello, Elisabeth Wassner-Fritsch, Laurie H Sehn

Blood (2016) 128 (22): 615.

https://doi.org/10.1182/blood.V128.22.615.615

Published: 2016

Journal Articles

Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions

Ciara L. Freeman, Franck Morschhauser, Laurie Sehn, Mark Dixon, Richard Houghton, Thierry Lamy, Günter Fingerle-Rowson, Elisabeth Wassner-Fritsch, John G. Gribben, Michael Hallek, Gilles Salles, Guillaume Cartron

Blood (2015) 126 (24): 2646–2649.

https://doi.org/10.1182/blood-2015-09-670802

Published: 2015

Journal Articles

Primary Results of the Health-Related Quality of Life Assessment from the Phase III Gadolin Study of Obinutuzumab Plus Bendamustine Compared with Bendamustine Alone in Patients with Rituximab-Refractory, Indolent Non-Hodgkin Lymphoma

Bruce D. Cheson, MD, Peter C Trask, PhD MPH, John Gribben, MDDSc, Natalie Dimier, Eva Kimby, MD PhD, Pieternella J Lugtenburg, MD PhD, Catherine Thieblemont, Elisabeth Wassner Fritsch, MD, Laurie H Sehn, MD MPH

Blood (2015) 126 (23): 1532.

https://doi.org/10.1182/blood.V126.23.1532.1532

Published: 2015

Journal Articles

Obinutuzumab (GA101) in Combination with CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) or Bendamustine for the First-Line Treatment of Follicular Non-Hodgkin Lymphoma: Final Results from the Maintenance Phase of the Phase Ib GAUDI Study

Martin JS Dyer, Andrew P Grigg, MBBS FRACP FRCPA MD, Marcos González Díaz, MD PhD, Martin Dreyling, Simon Rule, MD, Guiyuan Lei, PhD, Elisabeth Wassner-Fritsch, PharmD, Günter Fingerle-Rowson, MDPhD, Paula V Marlton, MBBS

Blood (2014) 124 (21): 1743.

https://doi.org/10.1182/blood.V124.21.1743.1743

Published: 2014

Journal Articles

Pattern of Cytokine Release in Patients with Chronic Lymphocytic Leukemia Treated with Obinutuzumab and Possible Relationship with Development of Infusion Related Reactions (IRR)

Ciara Louise Freeman, MRCP, MD, Franck Morschhauser, MD PhD, Laurie H. Sehn, MDMPH, Mark Dixon, Richard Houghton, Thierry Lamy, MD, Gunter Fingerle-Rowson, MD PhD, Elisabeth Wassner-Fritsch, Michael Hallek, MD, Gilles Salles, MD PhD, Guillaume Cartron, MD

Blood (2014) 124 (21): 4674.

https://doi.org/10.1182/blood.V124.21.4674.4674

Published: 2014

Journal Articles

Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study

Guillaume Cartron, Sophie de Guibert, Marie-Sarah Dilhuydy, Franck Morschhauser, Veronique Leblond, Jehan Dupuis, Beatrice Mahe, Reda Bouabdallah, Guiyuan Lei, Michael Wenger, Elisabeth Wassner-Fritsch, Michael Hallek

Blood (2014) 124 (14): 2196–2202.

https://doi.org/10.1182/blood-2014-07-586610

Published: 2014

Includes: Supplemental data

Journal Articles

Obinutuzumab (GA101) Plus CHOP Or FC In Relapsed/Refractory Follicular Lymphoma: Final Data From The Maintenance Phase Of The Phase 1b GAUDI Study (BO21000)

Andrew Davies, MRCP, PhD, John Radford, MD, Guillaume Cartron, MD, PhD, Franck Morschhauser, MD, PhD, Gilles Andre Salles, MD, PhD, Robert Marcus, MB, FRCP, FRCPath, Michael K Wenger, MD, Guiyuan Lei, PhD, Elisabeth Wassner-Fritsch, PharmD, Umberto Vitolo, MD

Blood (2013) 122 (21): 1814.

https://doi.org/10.1182/blood.V122.21.1814.1814

Published: 2013

Journal Articles

Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000)

John Radford, Andrew Davies, Guillaume Cartron, Franck Morschhauser, Gilles Salles, Robert Marcus, Michael Wenger, Guiyuan Lei, Elisabeth Wassner-Fritsch, Umberto Vitolo

Blood (2013) 122 (7): 1137–1143.

https://doi.org/10.1182/blood-2013-01-481341

Published: 2013

Journal Articles

Obinutuzumab (GA101) in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) or Bendamustine in Patients with Previously Untreated Follicular Lymphoma (FL): Results of the Phase Ib GAUDI Study (BO21000)

Martin JS Dyer, MA, DPhil, FRCP, FRCPath, Andrew Grigg, MBBS, FRACP, FRCPA, Marcos González, Martin Dreyling, Simon A. Rule, MD, Guiyuan Lei, Elisabeth Wassner-Fritsch, Michael K. Wenger, MD, Paula Marlton, MBBS, FRACP, FRCPA

Blood (2012) 120 (21): 3686.

https://doi.org/10.1182/blood.V120.21.3686.3686

Published: 2012

Journal Articles

Obinutuzumab (GA101) in Combination with FC or CHOP in Patients with Relapsed or Refractory Follicular Lymphoma: Final Results of the Phase I GAUDI Study (BO21000)

John Radford, MD, Andrew Davies, Guillaume Cartron, MD, PhD, Franck Morschhauser, MD, PhD, Gilles Andre Salles, Robert E. Marcus, MBBS, FRCP, FRCPath, Michael K. Wenger, Elina Asikanius, Elisabeth Wassner-Fritsch, Umberto Vitolo, MD

Blood (2011) 118 (21): 270.

https://doi.org/10.1182/blood.V118.21.270.270

Published: 2011

Journal Articles

Efficacy and Safety of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma: Results From a Phase I/II Study (BO20999)

Gilles Andre Salles, Franck Morschhauser, MD, PhD, Catherine Thieblemont, MD, Philippe Solal-Celigny, Thierry Lamy, MD, PhD, Herve Tilly, Pierre Feugier, MD, PhD, Steven Le Gouill, MD, PhD, Emmanuel Gyan, MD, PhD, Reda Bouabdallah, MD, Michael K. Wenger, MD, Elisabeth Wassner-Fritsch, Elina Asikanius, Guillaume Cartron, MD, PhD

Blood (2011) 118 (21): 268.

https://doi.org/10.1182/blood.V118.21.268.268

Published: 2011

Journal Articles

Encouraging Activity of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma: Results From a Phase II Study (BO20999),

Franck Morschhauser, MD, PhD, Guillaume Cartron, MD, PhD, Catherine Thieblemont, MD, Philippe Solal-Celigny, Corinne Haioun, MD, Reda Bouabdallah, MD, Thierry Lamy, MD, PhD, Noel Milpied, MD, Steven Le Gouill, MD, PhD, Pierre Feugier, MD, PhD, Michael K. Wenger, Elisabeth Wassner-Fritsch, Elina Asikanius, Gilles Andre Salles

Blood (2011) 118 (21): 3655.

https://doi.org/10.1182/blood.V118.21.3655.3655

Published: 2011

Journal Articles

Pharmacokinetics of Obinutuzumab (GA101) in Patients with CD20+ Relapsed/Refractory Malignant Disease Receiving Concomitant Chemotherapy (Phase Ib Study BO21000),

David Carlile, PhD, Georgina Meneses-Lorente, PhD, Elisabeth Wassner-Fritsch, Florence Hourcade-Potelleret, PhD, Michael K. Wenger, Guillaume Cartron, MD, PhD, Umberto Vitolo, MD, John Radford, MD, Andrew Davies, Franck Morschhauser, MD, PhD

Blood (2011) 118 (21): 3704.

https://doi.org/10.1182/blood.V118.21.3704.3704

Published: 2011

Journal Articles

Interim Results of a Phase I/II Study of Ocrelizumab, a New Humanised Anti-CD20 Antibody in Patients with Relapsed/Refractory Follicular Non-Hodgkin’s Lymphoma.

Franck Morschhauser, Paula Marlton, Umberto Vitolo, Ola Linden, John Seymour, Michael Crump, Bertrand Coiffier, Alessandro Pulsoni, Andrew Belch, Erika Lerch, Eva Kimby, Kristina Arnljots, Elisabeth Wassner, Myriam Mendila

Blood (2007) 110 (11): 645.

https://doi.org/10.1182/blood.V110.11.645.645

Published: 2007

NARROW

Biomarker Correlates and Clinical Activity of Cevostamab in Patients (pts) with Triple-Class Refractory Multiple Myeloma (MM) Who Have Received ≥1 Prior B-Cell Maturation Antigen (BCMA)-Targeted Bispecific Antibody (BsAb): Results from the Phase I/II CAMMA 2 Study

Dynamics of Activated CD8+ T-cells and Decreased Osteoclasts in the Tumor Microenvironment are Associated with Clinical Efficacy of Anti-PD-L1 and Anti-CD38 Combination Treatment in Relapsed or Refractory Multiple Myeloma

Atezolizumab in Combination with Daratumumab with or without Lenalidomide or Pomalidomide: A Phase Ib Study in Patients with Multiple Myeloma

Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN Study

Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions

Primary Results of the Health-Related Quality of Life Assessment from the Phase III Gadolin Study of Obinutuzumab Plus Bendamustine Compared with Bendamustine Alone in Patients with Rituximab-Refractory, Indolent Non-Hodgkin Lymphoma

Obinutuzumab (GA101) in Combination with CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) or Bendamustine for the First-Line Treatment of Follicular Non-Hodgkin Lymphoma: Final Results from the Maintenance Phase of the Phase Ib GAUDI Study

Pattern of Cytokine Release in Patients with Chronic Lymphocytic Leukemia Treated with Obinutuzumab and Possible Relationship with Development of Infusion Related Reactions (IRR)

Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study

Obinutuzumab (GA101) Plus CHOP Or FC In Relapsed/Refractory Follicular Lymphoma: Final Data From The Maintenance Phase Of The Phase 1b GAUDI Study (BO21000)

Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000)

Obinutuzumab (GA101) in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) or Bendamustine in Patients with Previously Untreated Follicular Lymphoma (FL): Results of the Phase Ib GAUDI Study (BO21000)

Obinutuzumab (GA101) in Combination with FC or CHOP in Patients with Relapsed or Refractory Follicular Lymphoma: Final Results of the Phase I GAUDI Study (BO21000)

Efficacy and Safety of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma: Results From a Phase I/II Study (BO20999)

Encouraging Activity of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma: Results From a Phase II Study (BO20999),

Pharmacokinetics of Obinutuzumab (GA101) in Patients with CD20+ Relapsed/Refractory Malignant Disease Receiving Concomitant Chemotherapy (Phase Ib Study BO21000),

Interim Results of a Phase I/II Study of Ocrelizumab, a New Humanised Anti-CD20 Antibody in Patients with Relapsed/Refractory Follicular Non-Hodgkin’s Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only